The Preconditioning Effect of Sevoflurane on Coronary Artery Bypass Surgery Patients by Anvaripour, Abdorasoul et al.
  Journal of Cellular & Molecular Anesthesia (JCMA)  
 Journal of Cellular & Molecular Anesthesia (JCMA) 
66 
Original Article  
 
 
The Preconditioning Effect of Sevoflurane on Coronary Artery 




Abdorasoul Anvaripour1, Houshang Shahryari1, Sayed Mehran Marashian2, Alireza Jahangirifard3* 
 
Abstract 
Background: One of the most important issues in the field of surgery is 
ischemic preconditioning (IPC) of the myocardium during the coronary artery 
bypass grafting (CABG). The current study attempted to reevaluate the issue to 
find a potential approach to diminish morbidity, inotrope administration, 
ischemia and possibly intensive care unit stay after CABG in adult patients.  
Materials and Methods: Through randomized single-blind clinical trial, all 
elective coronary bypass surgeries in 40 to 80 years-old patients enrolled the 
study. Atrioventricular (AV) block (mobitz2); complete heart block; left bundle 
branch block (LBBB); acute heart failure (ejection fraction (EF) <30%); re-
exploration due to surgical complications and MI cases in the last 7 days were 
excluded. In all patients, induction (sufentanil, cis-atracurium and etomidate) 
and maintenance phase (sufentanil, midazolam, cis-atracurium) of anesthesia 
were done following the same protocol. After cross-clamp of aorta in 
intervention group, the patients received oxygen (2Lit/min) and sevoflurane 
(4%) during coronary bypass surgery. After rewarming of the patients, 
sevoflurane was discontinued. Main outcome measures were troponin 4, 8, 24, 
48 hours after surgery with charting the electrocardiogram (ECG) changes, 
need for inotrope agents and hemodynamic indices during and after CABG in 
ICU.  
Results: 58 CABG candidates enrolled the current study: 29 in intervention 
group and 29 in control group. There were no statistical differences between 
the groups concerning hemodynamic issues, Central Venous Pressure (CVP), 
hematocrit (HCT), ECG changes, demands for inotrope, or ICU stay between 
the groups.  
Conclusion: No significant relationship between application of 4% 
sevoflurane and IPC was found in adult CABG patients. However, the effect of 
Sevoflurane on IPC might be dose-related.  
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Introduction 
Ischemic preconditioning (IPC) is a protective 
way to lessen the ischemia of myocardium. IPC is a 
natural defensive mechanism that helps the heart 
tolerate ischemic condition that firstly raised by Murry 
et al, in the 1986 (1, 2). In this process, many 
mechanisms are involved such as myocardial G-
protein paired receptors, adenosine A1 receptors and α1 
adrenergic receptors. Protein Kinase-C is another 
mediator involved as a cardiac potassium channel 
activator (1). 
Sevoflurane is one of the liquid general 
anesthetic medications affecting on ion channels, 
especially on receptors of acetylcholine, gamma-
aminobutyric acid (GABA) and glutamate. This 
anesthetic has several side effects such as malignant 
hyperthermia, dose-dependent hypotension, 
bradycardia, tachycardia, nausea and vomiting (3). 
Sevoflurane role has been shown as an inhaled 
anesthetic medication in protection through ischemic 
preconditioning (IPC) as well. Adenosine 
administration may induct IPC through previous 
experiences either before Coronary Artery Bypass 
Graft (CABG) or before being used along with 
cardioplegic solutions. IPC facilitates myocardial 
recovery after surgery via lower myocardial damage 
and decreased inotrope administration need.  
Through a meta-analysis in 2007, clinical trials 
to compare Sevoflurane and Desflurane were studied 
concerning mortality and morbidity after CABG to 
conclude protective effects of halogen-containing 
anesthetic medicinal diet on heart (4). In addition, a 
drop in hemodynamic side effects was shown by 
Annecke et al, using sevoflurane in pigs through 
general anesthesia compared to propofol as well as a 
decrease in cellular markers regularly released because 
of myocardial damage (5). 
Measuring Troponin-I four hours after surgery, 
as a marker of myocardial tissue damage, Frabdorf et 
al, found that two 5-min cycles of minimum dose of 
sevoflurane, 10-minute before external blood flow, 
obviously resulted in less myocardial damage 
comparing to intravenous Sufentanil and Propofol (6). 
They confirmed that Sevoflurane inducted strongly 
dose-dependent IPC. 
A comparison between interrupted and 
continuous administration of Sevoflurane and Propofol 
was carried out in 2008 by Bein et al, through CABG 
to realize that interrupted sevoflurane could 
prominently reduce myocardial damage based on a 
drop in Troponin-I and creatine phosphokinase-MB 
(CK-MB) (7). Later in 2014, Kortekaas et al, observed 
that cardio-specific Sevoflurane administration 
strongly reduced systemic inflammation without 
attenuating cell damage markers when used during 
mitral value repair surgery (8). 
Kawamura et al, in 2006 had assessed the effects 
of sevoflurane and Propofol on interleukin (IL)-10, IL-
8, IL-6 and IL-1 receptor antagonist (IL-1ra) in 23 
patients to know that Sevoflurane suppressed IL-6 and 
IL-8 release but had no obvious effect on IL-10 and IL-
1ra. They also raised the doubt that its protective role 
for myocardium may be resulted by a change in the 
balance between pre-inflammatory and anti-
inflammatory cytokines (9). 
Finally, two separate studies by Bouwman et al, 
and Lorsonradee et al, showed the key protective role 
of sevoflurane on cardiac contracture, kidney, and liver 
to get better recovery results (10, 11). 
In detail, Sevoflurane involves ca-dependent 
PKC-α channel to protect myocardium during IPC in 
addition to keeping serum glutamic-oxaloacetic 
transaminase (SGOT), serum glutamic pyruvic 
transaminase (SGPT), lactate dehydrogenase (LDH) 
and serum creatinine better than Propofol. 
Few studies have focused on the effects of 
Sevoflurane on cardiac preconditioning through 
CABG among which the optimal administration dose 
to get optimal protection was not precisely available. 
Therefore, the current study attempted to reevaluate the 
issue to find better way of diminish in morbidity, 
inotrope administration, and ischemia and 
consequently ICU stay after CABG. 
Methods 
Patients and sample size 
Through a randomized clinical trial, 58 patients 
of CABG were participated to be divided to two groups 
of intervention and control each containing 29 
regarding inclusion criteria. The participants were 40-
80 years of age who were candidates for elective 
CABG referred to a university hospital in Bushehr, 
Iran, between 2016 and 2017. Background information 
such as age, sex, ejection fraction, history of 
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myocardial infarction, cardiomegaly, angiotensin-
converting enzyme (ACE) inhibitors administration an 
also diabetes mellitus types I and  were basically 
recorded for all the participants. 
Simple randomization was done using random 
numbers to enter the patients into the named groups of 
this study. The sample size was calculated 30 patients 









α=0.05 β=0.8 d=0.04 Tn-I plasma level 
SD=4.5ng/ml 
Two patients had some lost information and 
were excluded from the study. 
 
Procedure process  
Premedication was done night before surgery as 
well as early morning at surgery date with Lorazepam 
and intramuscular injection of morphine regarding 
systolic blood pressure more than 100 mmHg, 30 
minutes before entering operation room. All cardiac 
medications except ACE inhibitors and anticoagulants 
(like Plavix®) continued until procedure date. Arterial 
line was inserted left radial or brachial arteries under 
local anesthesia with lidocaine immediately after 
entering the operation room. Tracheal intubation, 
pulse-oximetry, V2 and V5-lead ECG and capnography 
were carried out. All the participants experienced 
similar protocol of general anesthesia with 1-1.5 g/kg 
Sufentanil , 0.1 mg/kg Midazolam, 0.15-0.2 mg/kg 
Cis-atracurium and 0.2 mg/kg Etomidate followed by 
maintenance with 2g/kg/hour Sufentanil+ 
1g/kg/min Midazolam+2µg/kg/min Cis-atracurium. 
Revascularization was done via left internal mammary 
artery (LIMA) and saphenous vein. Cannulation of 
aorta and right atrium was then conducted after 300 
U/kg Heparin administration via central venous 
catheter while activated clotting time (ACT)>400 
seconds. Cardioplegic solution was cold liquid 
plasmalight (6°C) containing 165 mEq sodium 
chloride, 25 mEq sodium bicarbonate, 45 mEq 
potassium, 138 mEq chloride with 1800 cc prime 
volume. 
For the group of intervention, participants were 
administered sevoflurane 4% via vaporizer along with 
2 liters oxygen during bypass pump while oxygen was 
the only thing administered in the control group. 
Sevoflurane was withdrawn after rewarming. The 
patients were admitted in ICU after the procedure 
ended by closing sternum. Analgesia was done using 
an intravenous pump containing a mixture of 10 mg 
morphine 2 g Apotel, and 4 mg Ondansetron. 
Any changes in ECG showing ischemia as 
well as any ventricular arrhythmia, which needed 
medications (such as ventricular fibrillation (VF), 
ventricular tachycardia verotoxin (VT), or premature 
ventricular contractions (PVC)) beside atrial 
fibrillation atrial flutter amniotic fluid (AF) or atrial 
flutter, were recorded carefully. Ischemic changes of 
ECG follows:  
1- Q-wave myocardial infarction (MI) 
evidenced by the appearance of new persistent (<24 
hours) Q waves >0.04 seconds in greater than or equal 
to 2 contiguous leads of the same vascular territory or 
equivalent R-wave increments (R/S ratio >1 in leads 
V1and V2). 
2- A non–Q-wave MI was diagnosed by ST-
segment elevation or depression >1 mV 0.08 seconds 
after the J-point or T-wave inversion of 1 to 2 mV 0.08 
seconds after the J-point in 2 contiguous leads of the 
same vascular territory. 
Needed inotropes including Epinephrine, 
Norepinephrine, Milrinone and Vasopressin at the time 
of cardiopulmonary bypass (CPB) emerging was 
recorded as well. ECG changes were recorded at ICU 
admission time, 24 and 48 hours later. Serum troponin 
level was also recorded at 4, 8, 24 and 48 hours 
following operation. Systolic and diastolic blood 
pressure in addition to mean arterial pressure and heart 
rate were other parameters to record before anesthesia 
induction as well as 10 minutes, 60 minutes and 8 and 
24 hours after end of CPB. 
The current study was approved by the local 
ethics committee under the code: 
IR.BPUMS.REC1395.23 and finally by the ministry of 
health of Iran through approval number: 
IRCT2016061528477N1. 
Regarding 95% confidence interval and 
significance of 0.05, frequency, mean, standard 
deviation and range of changes were analyzed using 
Chi-Square test, Mann-Whitney U test, ANCOVA and 
Friedman by SPSS 24 for windows. 
The current study chiefly faced challenges such 
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as shortness in Sevoflurane stock as well as patient 
exclusion due to postoperative uncontrolled bleeding. 
 
Results 
Totally, 58 CABG candidates enrolled the 
current study including 29 in intervention group and 29 
in control group. The mean age was 56.24 ± 8.80 (45-
70 years) in the former group and 59.59±10.76 (31-81 
years) in the latter with no significant difference 
(Mann-Whitney U: P value=0.348). 
Sex wise, no difference was found between the 
groups as can be seen in table 1 (X2(1) = 0.672; P 
value=0.585 by Fisher Exact test). There was no 
statistical difference between the groups concerning 
ejection fraction as checked with Mann-Whitney U (P 
value=0.177). 
Table 1 summarizes some key demographic as 
well as medical history of the participants regarding 
their groups. History of cardiomegaly (P =0.431), 
ACE-inhibitors (P =0.065) and diabetes mellitus type 
and  (P =0.248) was not statistically different at all. 
The serum level of troponin was the first 
concern, which showed similar results in intervention 
and control groups 4, 8, 24 and 48 hours after the 
surgery (Table 2). 
Another factor to be assessed was ECG changes 
after surgery including Q and non-Q-wave-MI which 
were similar in the studied groups as observed in table 
3. 
Similar results were found for the need of 
Inotropes during on-pump process (P>0.089) and 
continued during off-pump (P=0.412) (Table3). 
Inotropes were similarly needed through 
postoperative ICU stay as can be checked in table 3. 
(P=0.506) Inotrope need during intra-aortic balloon 
pump (IABP) did not differ between the groups 
(P=0.492). 
Concerning hemodynamic factors, no item but 
systolic blood pressure (P=0.020) and the mean arterial 
blood pressure (P=0.002) differed statistically when 
compared the groups preoperatively. After 60 minutes 
of pump phase, like what happened 7 hours later, 
statistically similar hemodynamic parameters were 
obviously found between the groups as can be seen in 
table 4 as well. This similarity was showed 24 hours 
after the pump phase (Table 4). 
In terms of hematocrit, findings shown no 
Table 1: Demographics and some histories of diseases and medications. 
 




Intervention 17 58.6 
Control 20 69 
Female 
Intervention 12 41.4 
Control 9 31 
Recent MI 
Yes 
Intervention 5 17.2 
Control 5 82.8 
No 
Intervention 24 17.2 
Control 24 82.8 
Cardiomegaly 
Yes 
Intervention 16 55.2 
Control 12 41.4 
No 
Intervention 13 44.8 
Control 17 58.6 
ACE-I 
Yes 
Intervention 10 34.5 
Control 18 62.1 
No 
Intervention 19 65.5 
Control 11 37.9 
History of type 1 
Diabetes Mellitus 
Yes 
Intervention 3 10.3 
Control 26 97.7 
No 
Intervention 3 10.3 
Control 26 97.7 
History of type 2 
Diabetes Mellitus 
Yes 
Intervention 11 37.9 
Control 6 20/7 
No 
Intervention 18 62.1 
Control 23 97.3 
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statistical discrepancy between the studied groups at 
basic time and 15 mins and 30 mins later like at the end 
point of pump phase (Table 5). Likely, basic CVP 
(central vein pressure) and post-pump CVP were 
statistically similar in the groups (Table 6). 
Graft number showed the means of 3±0.13 
(±SE) and 3±0.18 in the groups of intervention and 
control respectively with no statistical difference 
reported by Mann-Whitney U (P value=0.950). 
Two complications including ventricular 
fibrillation (VF) and ventricular tachycardia (VT) were 
assessed for occurrence to find similar frequency in the 
groups (P value>0.05). 
 
Discussion 
The current study attempted to find positive 
effect of Sevoflurane on general anesthesia among 58 
CABG surgeries with less hemodynamic and ECG 
changes finally to confirm similar responses compared 
to regular techniques of intravenous anesthesia.  
Lemoine et al, in 2017 investigated cardio 
protective effects of sevoflurane through elective on-
pump CABG surgery compared with no halogenated 
volatile anesthesia to conclude that sevoflurane could 
half the cardiac troponin  in serum of what seen in 
controls as well as less need to inotropic support (12). 
At the same time, Wang et al, tried to reveal the 
biological mechanism involving in sevoflurane-
induced anesthesia in CABG surgery based on gene 
expression features to realize that neuroactive ligand-
receptor interaction may play the main role in cardio 
protective effects of sevoflurane through regulating the 
pathway (13). 
Zhang et al, in 2016 tried to compare the effects 
of Sevoflurane and regular method of general 
anesthesia only with inhaled oxygen regarding cardiac 
enzymes and hemodynamic features to find that 
Sevoflurane provided lower mean of arterial pressure, 
heart rate and left ventricle ejection fraction (LVEF) as 
well as significantly lower plasma level of CK-MB. 
Additionally, they studied respiratory parameters like 
tidal volume and vital capacity, respiratory rate and 
PaO2/Fio2 to get fluctuated data not enough to assess 
sevoflurane-related improvements. However they 
realized that Sevoflurane, despite lower LVEF, may 
contribute to Stabilization of cardiopulmonary 
function and prevention of myocardial injury (14). 
  
Table 2: Serum troponin levels at evaluating times. 
 
Troponin Group Mean SD Min Max P-value 
4 hours 
afterwards 
Intervention 3.56 2.73 0.50 12.12 0.859 
Control 3.81 3.27 0.06 15.55 
8 hours 
afterwards 
Intervention 5.58 7.28 0.43 32.00 0.446 
Control 5.17 5.28 0.62 50.25 
24 hours 
afterwards 
Intervention 3.72 4.21 0.15 18.00 0.525 
Control 5.24 10.12 0.30 56.00 
48 hours 
afterwards 
Intervention 2.15 2.63 0.00 8.80 0.294 
Control 3.74 8.79 0.12 48.70 
 
Table 3: ECG changes at different times of the study. 
MI Group N (%) P-value 
 
Q wave MI 
Intervention 0(0.00)  
>0.05 
 Control 1(3.30) 
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A meta-analysis showed in 2016 demonstrated 
no statistical difference between data about 
postoperative CK-MB levels among total 384 patients 
undergoing on-pump CABG with Sevoflurane; though 
postoperative myocardial troponin levels were 
significantly lower in sevoflurane group (15). 
Table 4: Hemodynamics at different points of the study regarding the groups* 
Hemodynamics Group Mean SD Min Max P-value 
SBP 
Intervention 152.71 26.53 100.00 200.00 
0.020 
Control 169.54 23.08 120.00 220.00 
DBP 
Intervention 73.27 11.41 50.00 100.00 
0.620 
Control 74.61 10.56 50.00 100.00 
MAP 
Intervention 96.27 13.42 72.00 115.00 
0.002 
Control 110.24 16.25 80.00 153.00 
HR 
Intervention 79.84 15.67 47.00 115.00 
0.982 
Control 80.74 15.89 50.00 113.00 
MAP15 
Intervention 60.74 9.13 45.00 76.00 
0.849 
Control 62.04 9.25 40.00 76.00 
MAP30 
Intervention 65.17 7.75 52.00 81.00 
0.812 
Control 66.00 9.53 48.00 85.00 
End-Pump 
Intervention 54.94 10.74 36.00 72.00 
0.538 
Control 58.14 11.21 40.00 85.00 
SBP after 10 min 
Intervention 119.31 11.21 99.00 141.00 
0.140 
Control 114.27 9.96 90.00 133.00 
DBP after 10 min 
Intervention 56.81 6.08 45.00 70.00 
0.941 
Control 56.81 6.39 45.00 70.00 
MAP after 10 
min 
Intervention 73.07 6.32 65.00 85.00 
0.486 
Control 74.14 6.65 58.00 86.00 
HR after 10 min 
Intervention 100.27 8.31 80.00 116.00 
0.554 
Control 98.44 9.77 78.00 116.00 
SBP60min 
Intervention 127.91 13.49 100.00 160.00 
0.351 
Control 124.34 13.41 100.00 145.00 
DBP60min 
Intervention 62.74 9.09 46.00 80.00 
0.599 
Control 63.81 8.85 48.00 80.00 
MAP60min 
Intervention 81.77 11.98 67.00 111.00 
0.545 
Control 109.27 153.65 65.00 921.00 
HR60min 
Intervention 94.27 9.87 75.00 117.00 
0.841 
Control 92.54 18.57 10.00 115.00 
SBP8hrs 
Intervention 138.57 19.56 90.00 180.00 
0.116 
Control 140.11 18.94 101.00 190.00 
DBP8hrs 
Intervention 75.71 12.02 54.00 105.00 
0.491 
Control 72.91 10.18 50.00 89.00 
MAP8hrs 
Intervention 95.24 16.72 68.00 138.00 
0.637 
Control 91.21 16.51 62.00 128.00 
HR8hrs 
Intervention 95.07 14.22 67.00 121.00 
0.894 
Control 96.17 10.66 75.00 118.00 
SBP24hrs 
Intervention 133.91 16.93 103.00 167.00 
0.220 
Control 137.84 17.86 107.00 170.00 
DBP24hrs 
Intervention 72.17 11.32 53.00 100.00 
0.801 
Control 72.54 11.21 51.00 91.00 
MAP24hrs 
Intervention 88.51 17.33 58.00 132.00 
0.674 
Control 89.34 14.19 60.00 129.00 
HR24hrs 
Intervention 91.47 11.13 73.00 110.00 
0.599 
Control 90.11 12.17 69.00 117.00 
*SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; MAP: Mean Arterial Pressure 
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The current study showed reduced length of 
ICU stay among patients who took Sevoflurane during 
surgery which was previously pointed out by 
Likhrantsev et al, in 2016 (16). The named study also 
confirmed reduced serum levels of cardiac biomarkers 
like troponin T and N- terminal pro-brain natriuretic 
peptide as well as mortality. 
Sirvinskas et al, raised mitochondrial function 
involvement in 2015 to explain the effects of 
Sevoflurane on clinical parameters in CABG surgery 
to believe that Sevoflurane could slightly protect the 
mitochondrial outer membrane from ischemia-
reperfusion injury and the loss of cytochrome C in 
addition to its significantly lower postoperative serum 
troponin levels when compared to Propofol. (17) 
However, little changes in hemodynamics through the 
current study were probably due to low dose of 
Sevoflurane to use; and higher doses may strengthen 
the protective features. 
Regarding clinical and basic studies on the 
effects of harm reduction of CABG surgery, there are 
many aspects of studies to perform to get enough 
reliable documents about protective role of sevoflurane 
in cardiac safety during and after the named surgery. 
Conclusion 
The current study could not find significant 
clinical effect and additional benefit of sevoflurane on 
ischemic preconditioning with the used dosage in on-
pump CABG surgeries. The effect of sevoflurane is 
probably dose-dependent which would be, in turn, a 
hypothesis to assess through more future trials as we 
believe. 
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